Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A loss |
Therapy | HMN-214 + Palbociclib |
Indication/Tumor Type | pancreatic cancer |
Response Type | decreased response |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A loss | pancreatic cancer | decreased response | HMN-214 + Palbociclib | Preclinical | Actionable | In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567). | 25156567 |
PubMed Id | Reference Title | Details |
---|---|---|
(25156567) | CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. | Full reference... |